Category Research

Grifols Sets Record with Highest Score in 2024 S&P Global Sustainability Assessment

Grifols Achieves Record Score in 2024 S&P Global Corporate Sustainability Assessment Grifols Secures 70 Points, Demonstrating a Seven-Point Improvement Over Previous Year Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company and manufacturer of plasma-derived medicines, has…

Read MoreGrifols Sets Record with Highest Score in 2024 S&P Global Sustainability Assessment

Jazz Pharmaceuticals Reports Positive Survival Results for Zepzelca® and Atezolizumab in Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced promising top-line results from a Phase 3 clinical trial assessing the effectiveness of Zepzelca® (lurbinectedin) combined with the PD-L1 inhibitor atezolizumab (Tecentriq®). This combination therapy was evaluated as a maintenance treatment for adults…

Read MoreJazz Pharmaceuticals Reports Positive Survival Results for Zepzelca® and Atezolizumab in Lung Cancer

Gilead Shares New Efficacy, Safety, and Demographic Data from PURPOSE 2 Trial at HIV Research for Prevention Conference

Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor, for HIV prevention among a diverse group of cisgender men…

Read MoreGilead Shares New Efficacy, Safety, and Demographic Data from PURPOSE 2 Trial at HIV Research for Prevention Conference

CD137 Antibodies Clinical Trials & Market Opportunities 2027 – Over 80 Drugs in Development

The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in cancer immunotherapy. Its potential lies in its ability to stimulate…

Read MoreCD137 Antibodies Clinical Trials & Market Opportunities 2027 – Over 80 Drugs in Development

PharmaLegacy Acquires BTS Research, Expands Preclinical Services into North America

PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks a significant milestone for PharmaLegacy as it strengthens its global…

Read MorePharmaLegacy Acquires BTS Research, Expands Preclinical Services into North America

Jazz Pharmaceuticals to Showcase Breakthroughs in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain. The presentations will highlight advancements in solid tumor…

Read MoreJazz Pharmaceuticals to Showcase Breakthroughs in Solid Tumor Oncology Research at ESMO 2024

Correction OMNY Health Expands GLP-1 Patient Network to Over 600,000 for Enhanced Clinical Research

OMNY Health, a leader in creating compliant cross-industry data partnerships, has announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, reinforcing its mission to democratize healthcare data. This new network, encompassing over 600,000 patients, will empower OMNY’s partners in…

Read MoreCorrection OMNY Health Expands GLP-1 Patient Network to Over 600,000 for Enhanced Clinical Research